Tag Archives: MTC

PR Newswire

A Comprehensive Introduction of the oneClick+ antigen platform

Leave a comment

SHANGHAI, Oct. 22, 2024 /PRNewswire/ — Sanyou Bio provides oneClick+ antigen one-stop solution, from antigen analysis to personalized preparation, to help tumor immunotherapy research and development. oneClick+ antigen platform is designed to provide high-quality annotation-related protein sequences, including protein amino acid sequences, isoelectric points, subcellular localization, structural domains, modification sites, and other properties, and to demonstrate non-redundant datasets, which help scientists to simplify the antigen analysis process and solve antigen expression difficulties. Sanyou provides high quality protein expression products covering mammalian, insect and bacterial expression, three major high quality protein expression systems to help your protein expression research.

oneClick+ Antigen Access Address
Visit https://www.oneclick-plus.com/. Start accessing the oneClick+ platform and select “Design Antigen”, to begin a one-stop shop for your antigen information. 

Platform Highlights

  1. Simplified input operation
    The oneClick+ platform for antigen analysis only requires you to enter the Uniprot ID corresponding to the protein. If you need to place a customized order, you can also select the desired expression system, protein amount, and other notes.
  2. Output Sequence Full Visualization
    The report outputs the amino acid sequences of the corresponding proteins, and proteins with > 2000 amino acids can also be displayed completely.
  3. Simplification of output information
    The output report demonstrates the physicochemical properties of the relevant antigen, including the number of amino acids, molecular weight, isoelectric point, subcellular localization, and protein type, in addition to the antigen’s transmembrane structural domains, signal peptide and modification sites, and three-dimensional structural features, which filters out redundant information and reduces the time required to find information.
  4. Protein preparation difficulty evaluation function
    Sanyou Bio extracted the data of 56,547 proteins from Uniprot database, and analyzed the number of amino acids, cysteines and glycosylation sites at the amino acid level, and issued a protein preparation difficulty assessment, which is intended to be a reference for scientists to judge the difficulty of protein preparation. (You can click Protein preparation difficulty assessment to see the specific analysis process.)
    (Note: Due to the diversity of proteins and other multifaceted factors, the following is not a foregone conclusion and is for reference only.)
  5. Free reports to help research
    To obtain antigen information report outputs through the oneClick+ platform, you can enter your email, and we will send them to you in the form of a zip package. In addition, if you have any antigen customization needs or other questions, you can also leave your contact information and we will contact you within 24 hours.
PR Newswire

HoneyNaps actively supplies “AI solutions” to U.S. medical institutions

Leave a comment
  • Rapid commercialization and delivery to the U.S. after FDA approval
  • Aiming to achieve a 10% market share within three years
  • Aggressive sales and expansion of distribution network through U.S. subsidiaries

BOSTON, Oct. 7, 2024 /PRNewswire/ — HoneyNaps announced on September 9th that it has officially begun exporting by delivering its artificial intelligence sleep disorder diagnostic software “SOMNUM” to two medical institutions in the U.S.

eXplainable A.I, SOMNUM
eXplainable A.I, SOMNUM

The SOMNUM solution supplied to the U.S. is the third globally to receive approval from the U.S. Food and Drug Administration(FDA) in 2023. It is not just a system for interpreting biometric signal images, but a deep learning-based AI interpretation system capable of real-time analysis of multi-channel/temporal and large-scale biometric signals, developed using the world’s first explainable medical AI (XAI, eXplainable AI) technology.

The SOMNUM solution will be introduced into research on sleep health for seniors and the verification of sleep improvement programs. HoneyNaps has signed a licensing agreement based on annual usage fees for the software.

HoneyNaps is currently strengthening its B2B business with major companies in South Korea while simultaneously focusing on local sales through its U.S. subsidiary in Boston and its West Coast dealer channels, expecting continuous growth in export volume.

A HoneyNaps representative said, “The U.S. is the largest sleep medicine market in the world and still holds significant growth potential. As we officially enter the U.S. market, we will solidify our business strategy to achieve a 10% market share within three years.”

For further information, please contact:
HoneyNaps USA, Inc.
Christine Kwon / Managing Director
Email: sleep@honeynaps.com
Address: , 5th Fl., 361 Newbury Street, Boston, MA 02115
Website: www.honeynaps.com

PR Newswire

CSafe launches reusable Silverpod pallet shipper to help pharma companies save on disposal costs and hit sustainability targets

Leave a comment

New pallet improves cost and operational efficiency while reducing environmental impact; includes real-time visibility with cloud connectivity

Key features include:

  • Made of fully reusable components and recyclable PCM (phase change material) refrigerants
  • New integrated real-time tracking device tracks GPS location, temperature, shock and tilt
  • Rental model reduces disposal costs and inconvenience, supported by CSafe’s recycle-reuse program
  • Available to pharmaceutical businesses and freight forwarders worldwide

MONROE, Ohio, July 29, 2024 /PRNewswire/ — CSafe, the provider of active and passive temperature-controlled shipping solutions for the pharmaceutical industry, has announced the launch of a new reusable pallet shipper – the Silverpod MAX RE – with a host of updated features. The new and improved product will help pharmaceutical customers around the world save on disposal costs, meet their sustainability targets and improve logistical transparency during the shipping journey.

Silverpod MAX RE
Silverpod MAX RE

CSafe has taken its globally recognized, single-use Silverpod MAX passive pallet shipper and enhanced it for reuse to create Silverpod MAX RE – a highly durable PCM pallet shipper made entirely of reusable components. This product directly assists the industry in hitting newly-imposed and increasingly stringent sustainability targets, contributing to a more sustainable shipping industry.

New features also include a built-in TracSafe RLT data logger for tracking the location of the shipment, which integrates with CSafe Connect (CSafe’s integrated digital supply chain ecosystem). This enables customers to get real-time visibility of their shipments throughout the entire journey. It also monitors payload temperature, external ambient temperature, shock, tilt and GPS location.

The new shipper, which offers 120+ hours of qualified thermal protection, is made from durable exterior panels with extended edge and corner cap protection that can be used time and time again. It’s supplied via a rental model where CSafe fully manages the life cycle and return of the product, eliminating disposal costs and inconvenience for the customer. The product is supplied flat-packed for the most cost-effective delivery, storage and assembly.

Patrick Schafer, CSafe CEO, said: “Reusability and quality are a major focus for pharmaceutical businesses needing to meet their sustainability targets, and we want to make it as easy as possible for them. With the Silverpod MAX RE, we’ve turned one of our best-loved flagship shippers into a fully sustainable product, while maintaining the high quality and best-in-class technology that CSafe is known for.”

For more information, visit https://csafeglobal.com/bulk-air-cargo/silverpod-max-re/#tech-specs

About CSafe
CSafe offers the pharmaceutical cold chain a broad suite of thermal shipping solutions worldwide. With a “patient-first” focus, deep expertise and commitment to innovation, CSafe matches your requirements to the best solution for your needs. Offering nearly any size, duration and temperature – CSafe is at the heart of your cold chain. csafeglobal.com

Press contact
Dominic Alston, Ballou PR
dominic.alston@balloupr.com
csafe@balloupr.com

CSafe
CSafe
PR Newswire

Australasian College of Pharmacy and MedAdvisor Solutions Launch MedAdvisor software training for the Queensland Community Pharmacy Scope of Practice Pilot

Leave a comment

Uplifting pharmacists’ role in primary care and positioning pharmacies as essential care destinations in local communities 

CAMBERWELL, Australia, July 25, 2024 /PRNewswire/ — MedAdvisor Solutions and the Australasian College of Pharmacy today announced the launch of the MedAdvisor software training – Queensland Community Pharmacy Scope of Practice Pilot. The training, conducted by MedAdvisor Solutions trained pharmacy managers, provides pharmacists with the essential training for the Queensland (QLD) Scope of Practice Pilot ensuring pharmacists are equipped to manage the conditions and services included in the Pilot.

The software training is continuing professional development (CPD) accredited and focuses on accessing the MedAdvisor Solutions platform to manage user accounts, complete patient medication details, message clinicians, and use the Queensland Scope of Practice forms when prescribing, and setting booking availability. By participating in the Pilot pharmacists will enhance their ability to improve medication management and healthcare delivery for patients across Australia.

“We are excited to take another step forward in supporting Australian pharmacists by giving them the ability to expand their scope of practice,” said Wayne Marinoff, MedAdvisor Solutions President ANZ. “The Pilot represents a significant step towards enabling pharmacists to practise at the top of their scope. In doing so, we are moving towards a future where pharmacists operate outside the dispensary and offer more comprehensive healthcare solutions for patients all over the country, while leveraging technology to support better health outcomes.” 

MedAdvisor Solutions is the preferred software partner for the delivery of expanded scope of practice across community pharmacies in Australia, helping to integrate the pharmacist as a key stakeholder in primary patient care and positioning pharmacies as primary healthcare locations in local communities.

Today’s announcement builds upon MedAdvisor Solution’s commitment to empower pharmacies with the tools and resources needed to enhance patient care, streamline pharmacy operations, and meet the evolving healthcare needs of our communities. The company is dedicated to supporting Australian pharmacies in delivering a broader range of healthcare services and today’s training initiative is just one component of the broader efforts.

About MedAdvisor Solutions

MedAdvisor Solutions is a global leader of pharmacy-driven patient engagement solutions that provide individualized patient experiences to simplify the patient medication journey. Our solutions utilise an empathetic, data-driven approach to engagement and an innovative, patient-centric digital experience that empower the pharmacy of the future and inspire lasting behaviour change. MedAdvisor Solutions works with over 37,000 pharmacies across the US, Australia & New Zealand to deliver our solutions to help patients take their medication safely and effectively.

In Australia, MedAdvisor Solutions has connected over 3.7 million patients through more than 95% of Australian pharmacies. MedAdvisor Solutions is on track to become one of the largest players to aid in the global transformation of the pharmacy of the future through digital patient engagement solutions.

www.medadvisorsolutions.com

About Australasian College of Pharmacy

The Australasian College of Pharmacy is a leading education and training provider for the pharmacy industry. The College provides lifelong learning for pharmacy students, pharmacy assistants, interns, pharmacists, and proprietors.

https://www.acp.edu.au/

Press Contacts:

Ancila Desai
Chief Financial Officer and Company Secretary                    
corporate@medadvisorsolutions.com                     
+61 3 9095 3036

Belinda Connolly
Marketing Manager
Australasian College of Pharmacy
connollyb@qldguild.org.au

Logo – https://techent.tv/wp-content/uploads/2024/07/australasian-college-of-pharmacy-and-medadvisor-solutions-launch-medadvisor-software-training-for-the-queensland-community-pharmacy-scope-of-practice-pilot.jpg

Logo – https://techent.tv/wp-content/uploads/2024/07/australasian-college-of-pharmacy-and-medadvisor-solutions-launch-medadvisor-software-training-for-the-queensland-community-pharmacy-scope-of-practice-pilot-1.jpg

PR Newswire

Clarivate Enhances Cortellis CMC Intelligence with Post-Approval Module to Accelerate Regulatory Success

Leave a comment

Enhancements enable pharma, biotech and generics companies to streamline regulatory tracking and optimize life cycle management for small molecules and biologics 

LONDON, May 2, 2024 /PRNewswire/ — Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced the launch of the newly enhanced Cortellis CMC Intelligence™ solution, featuring a new post-approval variations module. The module for post-approval variations covers regulatory changes across multiple countries, offering meticulously curated requirements to streamline tracking. With this update, pharmaceutical, biotech, and generics companies can effortlessly navigate the regulatory process and prioritize essential actions.

CMC activities account for nearly 18% of the entire R&D budget, emphasizing the importance of optimization and validation. Cortellis CMC Intelligence for post-approval variations enables clients to compare requirements across 64 countries, reducing tracking time and increasing submission rates with organized, timely, and accurate information.

Justin Hubbard, Vice President, Product Management, Life Sciences & Healthcare, Clarivate, said: “This enhancement underscores our commitment to simplifying the complexities of CMC regulatory dossier submissions for our clients. By offering transformative insights, Clarivate accelerates their path to markets and patients. With the ability to efficiently compare regulations across countries for small molecules and biologics, as well as automate CMC regulatory monitoring through user-configured alerts, clients can navigate the process with confidence.” 

With its new module covering both pre- and post-approval documents, Cortellis CMC Intelligence offers comprehensive lifecycle information for drugs and biologics. Serving as a single-platform solution for CMC requirements, it effectively reduces tracking time and unnecessary costs.

About Cortellis CMC Intelligence

Cortellis CMC Intelligence curates and tracks official CMC regulations and local practices for more than 135+ countries, territories and organizations for small molecules and 64 countries, territories and regions for biologics, with pre-and post-approval module coverage. Robust data is available for 25+ product and regulatory-related filters based on eCTD structure, including 6K+ source documents and over 2K links to Cortellis Regulatory Intelligence, providing access to expanded detail and in-depth summaries from experts in local regulatory practices, paired with reference source documents, to offer a complete picture. The addition of a new post-approval module now makes a comprehensive CMC solution with complete lifecycle information for drugs and biologics to increase submission rates and avoid costly delays. To learn more about Cortellis CMC Intelligence, visit here.

About Clarivate
Clarivate™ is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government, Intellectual Property and Life Sciences & Healthcare. For more information, please visit www.clarivate.com 

Media Contact:
Luna Ivkovic
External Communications, Life Sciences & Healthcare
newsroom@clarivate.com

PR Newswire

On-Device AI Healthcare Company Noul Announces 2 Clinical Performance Studies at Pan-African Malaria Conference

Leave a comment

  • miLab showed almost equivalent to WHO-certified first-degree microscopy experts: Sensitivity of 94.4%, Specificity of 98.1%
  • African authority on malaria diagnosis said “miLab is a potential game changer in accelerating access to parasitological confirmation”

YONGIN, South Korea, April 25, 2024 /PRNewswire/ — Noul Co., Ltd., (376930.KR), an On-Device AI healthcare company, announced that the results of a clinical performance study of its malaria diagnostic solution showed a sensitivity of 94.4%, and a specificity of 98.1%, which is almost equivalent to WHO-certified first-degree microscopy experts.

[Poster] Analytical Performance Experimentation assessment of the miLab™ MAL Malaria system for the detection of Plasmodium falciparum in clinical samples in Lagos, Nigeria
[Poster] Analytical Performance Experimentation assessment of the miLab™ MAL Malaria system for the detection of Plasmodium falciparum in clinical samples in Lagos, Nigeria

Noul participated in the Multilateral Initiative on Malaria Pan-African Malaria Conference (MIM PAMC) held in Kigali, Rwanda from April 21 to 27, and reveals two of the latest clinical performance studies conducted with its malaria diagnostic solution ‘miLab™ MAL’, in three major African countries, Nigeria, Ethiopia, and Ghana, through a poster presentation.

The study was conducted to verify the effectiveness of miLab™ MAL’s each use-case. And as a result, miLab™ MAL reached a sensitivity of 94.4% and a specificity of 98.1% for P. falciparum diagnosis, and a sensitivity of 97% and a specificity of 97.6% for P. vivax diagnosis. Based on these clinical achievements, Noul plans to actively promote cooperation with global research institutes and the health departments of each country. The achievements through collaborative research are expected to be published as papers within the year. 

Dr. Wellington A.Oyibo, a Chair of the Malaria Operational Research Expert Group of the National Malaria Program (MOREG) and a Professor of Lagos University who directed the research in Nigeria, said “miLab™ MAL is a potential game changer in accelerating access to parasitological confirmation and an asset to malaria control programs. Effective deployment of miLab™ MAL could provide critical data for accurately assessing malaria infection rates and severity, optimizing resource allocation and response strategies. This information is vital for health policymakers to design more effective prevention and case management programs.”

Dr. Taehwan Kim, Managing Director of noul GmbH said, “Africa is a huge single market, accounting for about 20% of the world’s population, and a place with 95.4% of the malaria burden occurring worldwide. By disclosing the excellent clinical performance of our malaria product at the conference involving the entire continent of Africa, we intend to establish specific cooperation relationships with key stakeholders in key markets such as global pharmaceutical companies and international organizations and actively seek new business opportunities.”

Meanwhile, the Multilateral Initiative on Malaria (MIM), established in 1997, is a global alliance of citizens, institutions, funding partners, and members united by the goal of enhancing scientific research capabilities in Africa and controlling and eradicating malaria. The Pan-African Malaria Conference (PAMC) is held every four years, marking its eighth anniversary this year. Major sponsors include the Bill & Melinda Gates Foundation and the Medicine for Malaria Venture (MMV).

About Noul

On-Device Healthcare Company, Noul is recognized for its innovative technology as the first AI-based diagnostic platform company in the blood and cancer sector, with miLab™ platform introduced as “the most advanced digital microscope and fully integrated bench-top platform” in UNITAID’s report in 2022.

Website https://noul.kr/en/

PR Newswire

China Medical University Hospital (CMUH) in Taiwan Upgrades Smart Healthcare with Gen AI

Leave a comment

Establishing a comprehensive “AI-assisted Physician” using generative AI from Google Cloud, including MedLM

TAICHUNG, Feb. 17, 2024 /PRNewswire/ — China Medical University Hospital (CMUH) in Taiwan announced its collaboration with Google Cloud in mid-December 2023. Using Google Cloud’s generative AI technology, including MedLM, which is a large language model built on Med-PaLM 2, CMUH has developed a comprehensive “AI-assisted Physician” system which aims to assist healthcare professionals in disease diagnosis, treatment planning, patient education, and medical research, etc. 

Superintendent Der-Yang Cho of CMUH announced a collaboration with Google Cloud to develop a large language model, MedLM, based on Med-PaLM 2. CMUH is the first medical center in Asia to adopt Med-PaLM 2.
Superintendent Der-Yang Cho of CMUH announced a collaboration with Google Cloud to develop a large language model, MedLM, based on Med-PaLM 2. CMUH is the first medical center in Asia to adopt Med-PaLM 2.

The collaboration between CMUH and Google Cloud will introduce assistive tools designed to support medical professionals in precision cancer treatment. These tools, including “Customized Cancer Treatment Guidelines” and “Cancer Therapy Q&As,” aim to reduce the time spent searching for information and enable the quick capture of accurate data. This can aid professionals in developing cancer treatment plans, offering personalized treatment-related information to patients, and providing responses to patient health education inquiries.

CMUH is one of the first university hospitals in Asia to test MedLM. Through its collaboration with Google Cloud, CMUH is dedicated to driving AI innovation in smart healthcare to shape the future of healthcare in Taiwan. MedLM will help facilitate CMUH in the timely access of accurate medical information to establish the best Healthcare AI models for the Chinese-speaking market in Asia.

Prof. Der-Yang Cho, Superintendent of CMUH, pointed out that MedLM is advanced in its ability to provide precise and rapid data analysis for drug guidelines, disease gene sequencing, and medical records, among other areas. Such capabilities can significantly accelerate the discovery of new treatments for difficult-to-treat diseases by medical teams and assist in the rapid development of treatment plans to help patients. “We are excited about this collaboration, which positions smart hospitals in Taiwan at the forefront of providing more precision- and safety-oriented support to healthcare professionals and patients alike,” Prof. Der-Yang Cho said.

CMUH was already recognized as the world’s third smart hospital by the US. Healthcare Information and Management Systems Society (HIMSS) in their 2022 Digital Health Indicator (DHI) ranking. Additionally, Newsweek named CMUH as one of the World’s Best Hospitals for 2023 and one of the World’s Best Smart Hospitals for 2024. With its widespread recognition, CMUH is deeply committed to advancing the diversification and precision of smart healthcare services.

“Life sciences problems are fundamentally data problems, and this is where AI can fully unleash its potential,” said Kathy Lee, Managing Director of Google Cloud, North Asia. “Generative AI solutions from Google Cloud can help healthcare and life sciences organizations operate more efficiently and improve patient outcomes. In this remarkable era of gen AI, we are excited to collaborate with medical industry leaders that drive innovation through AI like CMUH, and partner with them to build the future of healthcare in Taiwan.”

Aashima Gupta, Global Director of Healthcare Strategy and Solutions at Google Cloud, shared that healthcare professionals are committed to delivering the best care for patients, and gen AI can be a crucial ally in reducing their workload. Gupta pointed out that this technology will ease the cognitive burden for staff and improve personal care for patients. Furthermore, it will allow healthcare professionals at CMUH to devote more time to tasks that require human judgment and expertise. She mentioned that ensuring the safety and effectiveness of gen AI is fundamental to these benefits.

Greg Corrado, a Distinguished Scientist and Senior Research Director at Google Research, discussed how MedLM is designed specifically for the healthcare industry and is part of the growing family of gen AI technologies that have the potential to significantly improve the healthcare experience for professionals and patients. Corrado emphasized the importance of collaborating with healthcare institutions like CMUH in testing and implementing new gen AI solutions, underlining it as a critical step towards developing safe and effective AI technologies.

Prof. Oscar K. Lee, Vice Superintendent of CMUH explained that among global generative AI large language models, Med-PaLM 2 stands out in model performance. It scored 85% on MedQA-USMLE (US Medical Licensing Examination), reaching a level of excellence comparable to professional physicians. This makes it a pioneer among the world’s medical AI models in terms of outstanding performance. By training the model to analyze treatment guidelines and care cultures from various regions, MedLM will become even better at addressing the medical and healthcare needs of local populations.”

Currently, the collaborative applications between CMUH and Google Cloud include “Customized Cancer Treatment Guidelines” and “Cancer Therapy Q&As”. The “Customized Cancer Treatment Guidelines” are developed based on the National Comprehensive Cancer Network (NCCN) guidelines and are integrated with MedLM, enabling clinicians to quickly capture accurate information based on the patient’s cancer staging, treatment methods, and risk assessments, etc. It can also generate cancer treatment plans and provide personalized treatment recommendations for clinicians to review, edit and use with patients. Focusing on health education for cancer patients, the “Cancer Therapy Q&As” application incorporated the cancer care-related health educational content of CMUH into the MedLM model for training and optimization, resulting in a system with extensive medical knowledge and Q&A capabilities. Such advancement not only diminishes the time healthcare professionals spend searching for information but also provides comprehensive treatment options. Furthermore, it contributes to enhancing overall clinical efficacy, improving patient understanding and engagement, and enhancing the quality of healthcare, thereby fostering warmer doctor-patient interactions and steering us collectively toward a healthier future.

In addition, in terms of new drug development, CMUH is leveraging Google’s unique AI accelerators, TPU (Tensor Processing Unit), to assist in calculations related to protein folding and the development of new drugs. Preliminary tests at CMUH have shown that utilizing these resources can reduce the computation time for related programs by over tenfold.

With its robust research and development capabilities, CMUH’s Artificial Intelligence Center has provided over 20 distinct AI medical services in recent years, assisting doctors in making fast and accurate medical decisions.

Media contact: Carolyn Chen, 100709@tool.caaumed.org.tw

PR Newswire

Mindvalley Launches First Fully Immersive Meditation and Personal Development App on Apple’s Vision Pro

Leave a comment

Mindvalley is solo immersive Personal Development App Included on visionOS App Store 

KUALA LUMPUR, Malaysia and LONDON and NEW YORK and LOS ANGELES, Feb. 3, 2024 /PRNewswire/ — Mindvalley, the leading personal growth platform, is thrilled to announce the launch of its groundbreaking fully immersive meditation and personal development app on Vision Pro, Apple’s revolutionary spatial computing headset.

Mindvalley Vision Pro Launch

The app, jointly developed by Mindvalley and Oscar-winning creative studio, Framestore, represents a major breakthrough in personal development. With the integration of state-of-the-art virtual reality and audio technologies, users can now experience fully immersive meditations in breathtaking natural environments such as forests, deserts, and mountains. Additionally, the app offers a unique feature allowing users to practice and improve their public speaking skills through fully immersive simulations, in addition to Mindvalley’s extensive library of episodic personal growth content; Quests.

“We are incredibly excited about this collaboration with Apple,” said Vishen, Founder and CEO of Mindvalley. “Mindvalley was founded to help people push the boundaries of innovation and personal growth. By combining our passion for transformation with Apple’s cutting-edge technology, this app has the potential to revolutionize the way people approach meditation and personal growth.”

The collaboration between Mindvalley and Apple at the Vision Pro Developer Labs brought together two innovative forces in their respective industries. Mindvalley, known for its expansive library of online courses and programs, has impacted over 20 million lives worldwide by helping individuals unlock their full potential. Apple, renowned for its commitment to revolutionizing technology and creating seamless user experiences through its range of products and services, is on a continuous path of innovation.

As part of the Developer Labs, Mindvalley worked closely with Apple Worldwide Developer Relations in Singapore to integrate Vision Pro’s extraordinary capabilities with Mindvalley’s transformational content. Vision Pro offers high-quality displays, immersive environments, spatial audio, and advanced eye tracking, which were incorporated into the Mindvalley app to ensure an unparalleled level of immersion and interactivity.

“It was an honor to work with Apple’s amazing team in Singapore to gain unprecedented access to the Vision Pro as we developed the app,” said Manon Dave, Chief Product Officer of Mindvalley and Creative Technology Director at Framestore. “Vision Pro is the next step in personal computing, and we’re thrilled to have worked with Apple to bring Mindvalley to the forefront of wellness tech.”

To bring the experiences on the app to life, Mindvalley enlisted Framestore’s world-leading VFX and Immersive talent. “We are immensely proud to have collaborated with Mindvalley to bring forth a transformative experience for their users,” said Framestore CEO Mel Sullivan. “Partnering to integrate the unique capabilities of Apple Vision Pro was an extraordinary opportunity for our immersive team, leveraging our expertise honed in crafting world-class visuals for every screen. This project underscores our commitment to push the boundaries of technology while highlighting how innovation can be used to create a meaningful and impactful experience that resonates with people on a profound level.”

For more information about Mindvalley and their upcoming immersive app on Vision Pro, visit their website at www.mindvalley.com.

About Mindvalley:
Mindvalley is the world’s most powerful transformation platform that helps people step into their greatness. From longevity and wellness, to peak performance and spirituality, we provide cutting-edge programs from leading experts to help people achieve success and happiness and find fulfillment. Mindvalley’s learning platform, called ‘Quest’, introduces a new way of learning that delivers unparalleled results in human transformation. Mindvalley reaches more than 195 countries and has a vibrant community of 20 million passionate followers, boasting over 19,000 success stories and counting. Follow Mindvalley for more life-changing content at mindvalley.com or on social media: Instagram, Facebook, YouTube and TikTok.

About Framestore:
Framestore is a multi Academy Award-winning creative studio that combines talent and technology to reframe the possible in film, content, advertising and immersive experiences. Framestore is home to over 3,000 storytellers and innovators, united by a mission to bring life to everything they create. Founded in the UK in 1986, Framestore has studios in New York, LA, Chicago, Montreal, Vancouver, London, Melbourne and Mumbai.

Video – https://mma.prnasia.com/media2/2333273/Mindvalley_Vision_Pro_Launch_Sizzle.mp4

https://mma.prnasia.com/media2/2333273/Mindvalley_Vision_Pro_Launch_Sizzle.mp4
PR Newswire

PranaQ to Unveil Revolutionary Sleep Tech at CES 2024: Introducing TipTraQ, the AI Sleep Tracking and Improvement Solution

Leave a comment

NEW YORK, Jan. 16, 2024 /PRNewswire/ — PranaQ, the innovative sleep tech startup, has made waves at CES 2024 with the highly anticipated launch of its flagship product, TipTraQ. This cutting-edge device goes beyond traditional sleep monitoring, offering a comprehensive solution for diagnosing and monitoring respiratory sleep disorders, including sleep apnea, and improving sleep as a whole.

GenAI-Powered Sleep Improvement Program
TipTraQ goes beyond basic sleep monitoring by analyzing user-specific sleep trends, offering real-time tracking, and providing a personalized sleep coaching program powered by GenAI. PranaQ’s sleep improvement program not only tailors recommendations based on the individual’s data but also utilizes this information to find and direct users to the most beneficial treatment and solution options.

Medical-Grade Accuracy Validated by Leading US Medical Institutes
Rigorous testing and verification by leading medical institutes have confirmed the device’s exceptional precision in sleep breathing (including snoring) analysis, sleep stage assessment, and total sleep time tracking. PranaQ is proud to bring medical-grade sleep monitoring to consumers with TipTraQ.

Designed for Comfort and Everyday Use
TipTraQ blends cutting-edge functionality and user-centric design, creating a sleep-tracking solution pivotal for a connected and health-conscious future. Its ergonomic curve ensures comfort and signal quality, complemented by a featherlight design for daily use and an anti-slip strap for universal fit. Featuring eco-friendly components like a rechargeable battery and replaceable strap designed for long-term use, TipTraQ also serves as a key technology enabler for Smart Sleep and telehealth applications.

The Future of Sleep Tech at CES 2024
At CES 2024, PranaQ is proud to have showcased how TipTraQ helps consumers track and improve sleep and inspired them with a glimpse of firsthand experience of the future of sleep technology. With the partnership conversations that started at CES 2024 in Las Vegas, PranaQ can’t wait to collaborate with the sleep and wellness solution experts who showed an unshakable commitment to sleep health towards a common vision: help more people unlock their best sleep.

Media Engagement
For exclusive interviews, review units, demos, or additional information, please contact Alexandra Jones-Kuo at alexandra.joneskuo@pranaq.com

Stay updated on PranaQ’s sleep health journey and receive updates by subscribing to their newsletter or following them on LinkedIn and Instagram.

About PranaQ
PranaQ is committed to the future of IoMT and digital healthcare. We focus on patient-centric solutions and user wellness advocacy, supported by AI-powered wearable technology. Our goal is to empower people to gain more knowledge of their health conditions, more control of their medical treatments, and to improve their quality of life. For more information, visit https://pranaq.com.

PranaQ launches TipTraQ, its award-winning sleep tracking and improvement solution that features medical-grade accuracy and a personalized sleep coaching program powered by GenAI, at CES 2024.
PranaQ launches TipTraQ, its award-winning sleep tracking and improvement solution that features medical-grade accuracy and a personalized sleep coaching program powered by GenAI, at CES 2024.

PR Newswire

Ubie’s AI Symptom Checker Used by 2 Million Americans in First Year, Fueling Pharma Partnerships

Leave a comment

Ubie, a trailblazing AI-driven healthcare company, has achieved a new milestone with its AI Symptom Checker, surpassing 2 million uses in the U.S. in just over a year. Leveraging this expanding user engagement, Ubie is advancing its partnerships with pharmaceutical companies to promote early disease detection and treatment. Collaborations with industry giants like Takeda, Boehringer Ingelheim, and Pfizer exemplify Ubie’s extensive efforts across a broad range of medical conditions, promoting improved patient care through cutting-edge digital health solutions.

NEW YORK, Dec. 5, 2023 /PRNewswire/ — Ubie, a forerunner in the digital health arena, proudly announces a notable achievement that underscores its commitment to revolutionizing healthcare: Ubie’s AI Symptom Checker has been used more than 2 million times in the U.S. since its introduction to the market just over a year ago. This milestone demonstrates the significant traction the tool has gained among individuals eager to better understand and manage their health.

Since Ubie’s expansion into the U.S. market, the company has been focused on empowering individuals to recognize symptoms early and pursue timely healthcare discussions. This process provides users with in-depth insights into their symptoms, a comprehensive analysis of potential diseases, signs to look out for, and the ideal specialist to consult.

As an evidence-based AI company, data lies at the core of Ubie’s operations and Ubie’s unique relationship with its users allows the collection of differentiated quantitative and qualitative data. Based on user feedback, approximately 75% of patients plan to seek professional medical advice after checking their symptoms with Ubie, reflecting Ubie’s ability to promote high-value care. U.S. user stories illustrate the benefits of Ubie’s AI Symptom Checker:

  • A woman in her 30s, experiencing eye pain and dizziness, utilized the Symptom Checker, which suggested possible health concerns and the importance of a medical assessment. She was later diagnosed with multiple sclerosis (MS), validating the importance of early investigation into her symptoms.
  • An 80-year-old man was prompted by Ubie’s AI to consult a pulmonologist, which led to an early diagnosis of lung cancer, emphasizing the Symptom Checker’s role in early detection.
  • A woman in her 50s was guided by the Symptom Checker to seek medical attention for what turned out to be accurate identifications of bone diseases, highlighting the tool’s effectiveness in early symptom identification.
  • A 60s woman with dizziness mentioned, “The questions you asked matched all of my symptoms. Some I didn’t think to mention to my doctor at the time. I will raise them on my next visit. Thank you.”

Kota Kubo, CEO of Ubie, expresses his enthusiasm: “Surpassing 2 million uses in the U.S. in just a year is more than a number—it’s a marker of our growing role in helping Americans promptly address health concerns and seek professional care. Our technology is designed to complement the work of healthcare providers, bridging the gap from initial concern to professional care.”

Ubie’s collaborations with leading pharmaceutical companies demonstrate the effectiveness of digital health in addressing various medical conditions:

  • In Apr 2023, Ubie partnered with Takeda to tackle Hereditary Angioedema (HAE) through digital transformation initiatives (Press Release).
  • In Mar 2023, Ubie and Pfizer facilitated provider visits for over 17,000 OAB patients in Japan through the integration of “Ubie AI Symptom Checker” and “UUI Consultation Room” (Press Release)
  • In Feb 2022, Ubie worked with Boehringer Ingelheim on a project focused on Pulmonary Fibrosis, enhancing awareness and management of this condition (Press Release).

Recent press releases reflect Ubie’s commitment to enhancing the healthcare experience:

  • The launch of Ubie’s new Generative AI feature for doctors, improving medical record documentation with a 90% User Satisfaction rate (Press Release).
  • Partnership with Google’s Android platform “Health Connect (Beta)” as a launch partner in Japan (Press Release).
  • Successful closure of a $45 million Series C funding round and establish of a New York subsidiary (Press Release).

For more information about Ubie and its AI Symptom Checker, please visit Ubie AI Symptom Checker.

Contact:

Ryosei Hatakeyama
Ubie Inc.
1460 Broadway, New York, NY 10036
Email: pr@ubiehealth.com 

Note to Editors: For more details or to arrange an interview with CEO Kota Kubo, please reach out to Ryosei Hatakeyama at the contact information above.

Source: Ubie, Inc.